Skip to main content
. 2023 Aug 21;83(21):3636–3649. doi: 10.1158/0008-5472.CAN-22-3402

Figure 5.

Figure 5. Development of CDM for early-stage colorectal cancer diagnosis. A, Methylation levels of PBMCs DNA as quantified by the multi-msqPCR assay in 349 individuals (170 early-stage colorectal cancer and 179 healthy controls) from multiclinical sites, where a higher ΔCq value represents a higher methylation level. P values between different groups were determined by the Mann–Whitney U test. B, The ROCs demonstrate the performance of the multi-msqPCR assay for distinguishing early-stage colorectal cancer cases from healthy controls in multicenter cohort. C, A CDM score of 0.5252 was used as the cut-off value. Samples were classified as negative or positive according to the CDM score and the detection percentages are shown in the corresponding confusion matrix on the right. D, The ROCs of the CDM for the detection of early-stage colorectal cancer, advanced adenoma, and non–advanced adenoma cases. E, The multi-msqPCR assay was performed in 180 patients with different types of cancer (62 early-stage lung cancer cases, 55 early-stage breast cancer, and 63 early-stage gastric cancer). All samples were classified as negative or positive according to the cut-off value of 0.5252 and the classification results are shown in the corresponding confusion matrix on the right. AA, advanced adenomas; CDM, CRC diagnostic model; CRC, colorectal cancer; eGC, early-stage gastric cancer; eBC, early-stage breast cancer; eLC, early-stage lung cancer HC, healthy controls; non-AA, non-advanced adenomatous polyps.

Development of CDM for early-stage colorectal cancer diagnosis. A, Methylation levels of PBMCs DNA as quantified by the multi-msqPCR assay in 349 individuals (170 early-stage colorectal cancer and 179 healthy controls) from multiclinical sites, where a higher ΔCq value represents a higher methylation level. P values between different groups were determined by the Mann–Whitney U test. B, The ROCs demonstrate the performance of the multi-msqPCR assay for distinguishing early-stage colorectal cancer cases from healthy controls in multicenter cohort. C, A CDM score of 0.5252 was used as the cut-off value. Samples were classified as negative or positive according to the CDM score and the detection percentages are shown in the corresponding confusion matrix on the right. D, The ROCs of the CDM for the detection of early-stage colorectal cancer, advanced adenoma, and non–advanced adenoma cases. E, The multi-msqPCR assay was performed in 180 patients with different types of cancer (62 early-stage lung cancer cases, 55 early-stage breast cancer, and 63 early-stage gastric cancer). All samples were classified as negative or positive according to the cut-off value of 0.5252 and the classification results are shown in the corresponding confusion matrix on the right. AA, advanced adenomas; CDM, CRC diagnostic model; CRC, colorectal cancer; eGC, early-stage gastric cancer; eBC, early-stage breast cancer; eLC, early-stage lung cancer HC, healthy controls; non-AA, non-advanced adenomatous polyps.